DNA甲基化在肺癌发生及预后中作用的研究进展

doi:10.16352/j.issn.1001-6325.2023.03.514

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (3): 514-518.doi: 10.16352/j.issn.1001-6325.2023.03.514

DNA甲基化在肺癌发生及预后中作用的研究进展

薛剑超¹, 王亚东¹, 李博文¹, 刘新宇², 梁乃新^1*, 李单青¹

1.中国医学科学院北京协和医学院北京协和医院胸外科,北京 100730;
2.北京协和医学院临床医学八年制 2016级, 北京 100730

收稿日期:2021-10-25 修回日期:2022-05-07 出版日期:2023-03-05 发布日期:2023-02-27
通讯作者: * pumchnelson@163.com

Research progress on the role of DNA methylation in the occurrence and prognosis of lung cancer

XUE Jianchao¹, WANG Yadong¹, LI Bowen¹, LIU Xinyu², LIANG Naixin^1*, LI Shanqing¹

1. Department of Thoracic Surgery, Peking Union Medical College Hospital, CAMS & PUMC, Beijing 100730;
2. Grade 2016, Eight-year Program of Clinical Medicine, PUMC, Beijing 100730, China

Received:2021-10-25 Revised:2022-05-07 Online:2023-03-05 Published:2023-02-27
Contact: * pumchnelson@163.com

摘要/Abstract

摘要： 肺癌是中国发病率和病死率第一的肿瘤,早期复发是预后不良的主要原因。现存的预后指标不足以满足临床需要,亟需寻找可靠的预后指标。DNA甲基化是肺癌发生发展中最主要的表观遗传学改变,随着高通量测序技术的进展,其稳定易检测的特质在肺癌患者的预后预测中有着极大的临床应用价值。

关键词: 肺癌, DNA甲基化, 预后, 表观遗传学

Abstract: Lung cancer is a leading cause of cancer-related morbidity and mortality in China. Early recurrence is the main cause of poor prognosis. The existing prognostic indicators are insufficient. Thus, it is urgent to find reliable prognostic indicators. DNA methylation is the most important epigenetic change in the development of lung cancer. With the development of high-throughput sequencing technology, DNA methylation has shown its great clinical value in the prognosis prediction of lung cancer patients due to its stable and detectable features.

Key words: lung cancer, DNA methylation, prognosis, epigenetics

中图分类号:

R734.2

薛剑超, 王亚东, 李博文, 刘新宇, 梁乃新, 李单青. DNA甲基化在肺癌发生及预后中作用的研究进展[J]. 基础医学与临床, 2023, 43(3): 514-518.

XUE Jianchao, WANG Yadong, LI Bowen, LIU Xinyu, LIANG Naixin, LI Shanqing. Research progress on the role of DNA methylation in the occurrence and prognosis of lung cancer[J]. Basic & Clinical Medicine, 2023, 43(3): 514-518.

参考文献

[1]Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71: 209-249.
[2]Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016[J]. JNCC, 2022, 2: 1-9.
[3]Bird A. DNA methylation patterns and epigenetic memory[J]. Genes Dev, 2002, 16: 6-21.
[4]Brzeziańska E, Dutkowska A, Antczak A. The significance of epigenetic alterations in lung carcinogenesis[J]. Mol Biol Rep, 2013, 40: 309-325.
[5]Shi YX, Sheng DQ, Cheng L, et al. Current landscape of epigenetics in lung cancer: focus on the mechanism and application[J]. J Oncol, 2019. doi: 10.1155/2019/8107318.
[6]Hoang PH, Landi MT. DNA methylation in lung cancer: mechanisms and associations with histological subtypes, molecular alterations, and major epidemiological factors[J]. Cancers (Basel), 2022, 14:961. doi: 10.3390/cancers14040961.
[7]Ehrlich M. DNA methylation in cancer: too much, but also too little[J]. Oncogene, 2002, 21: 5400-5413.
[8]Soozangar N, Sadeghi MR, Jeddi F, et al. Comparison of genome-wide analysis techniques to DNA methylation analysis in human cancer[J]. J Cell Physiol, 2018, 233: 3968-3981.
[9]Duruisseaux M, Esteller M. Lung cancer epigenetics: from knowledge to applications[J]. Semin Cancer Biol, 2018, 51: 116-128.
[10]Peng X, Liu X, Xu L, et al. The mSHOX2 is capable of assessing the therapeutic effect and predicting the prognosis of stage IV lung cancer[J]. J Thorac Dis, 2019, 11: 2458-2469.
[11]Seok Y, Lee WK, Park JY, et al. TGFBI promoter methylation is associated with poor prognosis in lung adenocarcinoma patients[J]. Mol Cells, 2019, 42: 161-165.
[12]Villalba M, Exposito F, Pajares MJ, et al. TMPRSS4: a novel tumor prognostic indicator for the stratification of stage IA tumors and a liquid biopsy biomarker for NSCLC patients[J]. J Clin Med, 2019, 8:2134. doi: 10.3390/jcm8122134.
[13]Dong Y, Huaying S, Danying W, et al. Significance of methylation of FBP1 gene in non-small cell lung cancer[J]. Biomed Res Int, 2018. doi: 10.1155/2018/3726091.
[14]Liu WB, Han F, Huang YS, et al. TMEM196 hypermethylation as a novel diagnostic and prognostic biomarker for lung cancer[J]. Mol Carcinog, 2019, 58: 474-487.
[15]Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes ME, et al. Epigenetic prediction of response to anti-PD-1 treat-ment in non-small-cell lung cancer: a multicentre, retrospective analysis[J]. Lancet Respir Med, 2018, 6: 771-781.
[16]Han Y, Shi K, Zhou SJ, et al. The clinicopathological significance of hMLH1 hypermethylation in non-small-cell lung cancer: a meta-analysis and literature review[J]. Onco Targets Ther, 2016, 9: 5081-5090.
[17]Sandoval J, Mendez-Gonzalez J, Nadal E, et al. A prognostic DNA methylation signature for stage I non-small-cell lung cancer[J]. J Clin Oncol, 2013, 31: 4140-4147.
[18]Brock MV, Hooker CM, Ota-Machida E, et al. DNA methylation markers and early recurrence in stage I lung cancer[J]. N Engl J Med, 2008, 358: 1118-1128.
[19]Zhu Q, Wang J, Zhang Q, et al. Methylation driven genes PMPCAP1, SOWAHC and ZNF454 as potential prognostic biomarkers in lung squamous cell carcinoma[J]. Mol Med Rep, 2020, 21: 1285-1295.
[20]Gao C, Zhuang J, Li H, et al. Exploration of methylation-driven genes for monitoring and prognosis of patients with lung adenocarcinoma[J]. Cancer Cell Int, 2018, 18: 194. doi: 10.1186/s12935-018-0691-z.
[21]Kou W, Li B, Shi Y, et al. High complement protein C1q levels in pulmonary fibrosis and non-small cell lung cancer associated with poor prognosis[J]. BMC Cancer, 2022, 22: 110. doi: 10.1186/s12885-021-08912-3.
[22]Wang Y, Deng H, Xin S, et al. Prognostic and predictive value of three DNA methylation signatures in lung adenocarcinoma[J]. Front Genet, 2019, 10: 349. doi: 10.3389/fgene.2019.00349.
[23]Luo R, Song J, Xiao X, et al. Identifying CpG methylation signature as a promising biomarker for recurrence and immunotherapy in non-small-cell lung carcinoma[J]. Aging (Albany N Y), 2020, 12: 14649-14676.
[24]Koch A, Joosten SC, Feng Z, et al. Analysis of DNA methylation in cancer: location revisited[J]. Nat Rev Clin Oncol, 2018, 15: 459-466.

DNA甲基化在肺癌发生及预后中作用的研究进展

Research progress on the role of DNA methylation in the occurrence and prognosis of lung cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李顺乐, 李蓉, 田亚亚, 冉小丽, 赵延培, 徐蒙. 血清KLF5和actinin-4水平与肝细胞肝癌肝动脉化疗栓塞术治疗预后的关系[J]. 基础医学与临床, 2024, 44(9): 1284-1289.
[2]	侯楠, 刘源, 高俊, 王晶, 袁萌. 全血NPM1、MCP-1和肠道菌群与胃癌进展及预后相关[J]. 基础医学与临床, 2024, 44(8): 1137-1142.
[3]	郑红, 陈晓霞, 韩李周, 陈苗, 皇甫娟. 降低lncRNA-RMRP表达抑制人肺癌细胞系A549的增殖和侵袭[J]. 基础医学与临床, 2024, 44(7): 974-978.
[4]	操辰新, 唐辉, 耿瑞璇, 郭伏平, 白春梅, 王颖轶, 李太生. 循环CD4⁺CD45RA⁺CD62L⁺ T细胞与接受EGFR-TKI治疗的转移性非小细胞肺癌预后相关[J]. 基础医学与临床, 2024, 44(5): 658-664.
[5]	梁香存, 魏小雨, 梁健, 王庆, 耿广. 安罗替尼通过调控miR-16-5p/PD-1轴抑制人非小细胞肺癌细胞系增殖并促进凋亡[J]. 基础医学与临床, 2024, 44(4): 503-512.
[6]	张婧, 杨自更, 蔡文琴, 曹维维, 韦红梅, 薛茜茜, 吴宾. 抑制抗增殖蛋白2增强非小细胞肺癌细胞系A549对厄洛替尼敏感性[J]. 基础医学与临床, 2024, 44(3): 325-332.
[7]	李娟, 李晓峰, 徐生志, 唐凯. 华蟾素胶囊联合多西紫杉醇+顺铂化疗用于非小细胞肺癌患者的疗效[J]. 基础医学与临床, 2024, 44(2): 247-251.
[8]	丁飞, 王洒, 黄常新. 非小细胞肺癌患者血清CA211水平和NK细胞数与预后相关[J]. 基础医学与临床, 2024, 44(2): 180-184.
[9]	李文超, 李祥生, 李富光, 张志永, 惠磊, 周文科. 长链非编码RNA与疾病[J]. 基础医学与临床, 2024, 44(10): 1465-1469.
[10]	张伟, 张振, 杨连任, 梁伟. 肺癌7项抗体水平与NSCLC患者化疗效果及预后的关系[J]. 基础医学与临床, 2024, 44(10): 1383-1387.
[11]	周昕羽, 汤继宏, 肖潇, 冯隽, 杨乐天, 徐欢, 武银银. 儿童急性B淋巴细胞白血病合并化疗诱导周围神经病变的临床特点及预后分析[J]. 基础医学与临床, 2024, 44(10): 1394-1399.
[12]	王春燕, 王萍, 宋龙飞, 刘永全, 满君. LncRNA FEZF1-AS1通过调控EZH2对肺间质细胞增殖、迁移及侵袭的作用[J]. 基础医学与临床, 2024, 44(1): 43-50.
[13]	依马木买买提江·阿布拉, 帕哈尔丁·白克热, 易超, 佟庆. 血浆hsa_circ_005230在原发性肝细胞癌诊断和预后评估中的临床价值[J]. 基础医学与临床, 2023, 43(9): 1417-1422.
[14]	贡子琦, 吴晓雯, 郭倩, 郭军, 孔燕. PTEN突变对黏膜黑色素瘤患者临床病理特征及预后的影响[J]. 基础医学与临床, 2023, 43(9): 1341-1345.
[15]	颜晨红, 金儿. 外泌体PD-L1在非小细胞肺癌诊断和治疗上的研究进展[J]. 基础医学与临床, 2023, 43(9): 1457-1461.